tech for good

Houston nonprofit tests Comcast's new vision control technology for viewers with disabilities

The Easter Seals of Houston demonstrated new vision control technology from Comcast. Photo courtesy of Easter Seals

A local nonprofit organization has tapped into new technology from Comcast to benefit the community of people with visual disabilities and impairments.

In November 2014, the company announced the industry's first voice-enabled television user interface, a solution that allowed those who are blind or visually impaired to navigate the platform. In May 2015, Comcast announced the Xfinity remote with voice control. Later that same year, the company produced the first live entertainment show in U.S. broadcast history to be accessible to people with visual disabilities.

Continuing on this track of innovation, in June 2019, the company announced eye control for television. Any Xfinity user can now change the channel, set a recording, and search for a show using eye movement, working seamlessly with existing eye gaze hardware and software.

The Easter Seals Greater Houston demonstrated the new technology with their community, posted on the its YouTube page. The demonstration showcased the web-based remote for tablets and computers that pairs with an eye gaze system allowing viewers to control their smart TV.

"While eye gaze technology has existed for quite some time, last summer Comcast launched the Xfinity X1 eye control, which is a web-based TV remote for tablets and computers that pairs with an existing eye gaze system," says Cristen Reat, founder and program director of Easter Seals' BridgingApps. "This feature allows people with physical disabilities, such as Cerebral Palsy, ALS, and spinal cord injuries the ability to change the channel, set a recording and search for a favorite TV show with just their eyes."

Reat tells InnovationMap that most people who have significant physical disabilities are also nonverbal or have nonstandard speech, making a voice remote not a possibility.

"Now, with this new feature, they can do things without relying on a caregiver," says Reat.

The Comcast website states that X1 eye control is free and uses a web page remote control that works seamlessly with existing eye gaze hardware and software, Sip-and-Puff switches, and other existing assistive technologies. To use eye control, Xfinity customers can visit xfin.tv/access and use their Xfinity login credentials to pair the web-based remote with their set-top-box. Then, each time the customer gazes at a button, the web-based remote will send the corresponding command to the television.

"The response from clients we have demonstrated this with has been ecstatic," says Reat. "Something as simple as being able to change the channel independently, without relying on another person's help, can be life-changing."

Reat tells InnovationMap that Comcast and Easter Seals have collaborated in the past.

"We've been great partners, especially over the past few years," says Reat. "Because of that partnership, they reached out to us when they wanted to create awareness about this new feature."

"Changing the channel on a TV is something most of us take for granted but until now, it was a near-impossible task for millions of viewers," says Tom Wlodkowski, vice president of accessibility at Comcast in the product launch news release. "When you make a product more inclusive you create a better experience for everyone and we're hoping our new X1 feature makes a real difference in the lives of our customers."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted